BAC Water 10mL
Sterile water with 0.9% benzyl alcohol, used to reconstitute lyophilised peptides.

SKU: PCUK-TIRZ10 • Batch: 100269
Dual GIP/GLP-1 receptor agonist at 99.512% HPLC purity, supplied as a 10mg lyophilised vial with independent COA testing on every batch.
Read the full description ↓Price includes GST
✓Free shipping on orders over $250 AUD
✓Australia Post tracked — Standard $12.99 / Express $18.99
✓Dispatched next business day (orders before 11PM AEST)
Sterile water with 0.9% benzyl alcohol, used to reconstitute lyophilised peptides.
A mitochondria-targeted tetrapeptide studied for its affinity for cardiolipin.
Purity independently verified at a leading Australian university via HPLC & mass spectrometry.
Tirzepatide (LY3298176) is a dual receptor agonist targeting both the GIP and GLP-1 receptors. Supplied as a lyophilised powder at 99.512% HPLC purity with full Certificate of Analysis (COA) documentation.
We manufacture Tirzepatide ourselves, at our own GMP-compliant Australian facility, keeping chain-of-custody documentation intact from raw material through to dispatch. Every batch is independently verified by a third-party lab for HPLC purity, mass spectrometry identity, endotoxin levels (LAL, <1.0 EU/mg) and sterility before it ships.
Research has explored Tirzepatide's simultaneous activation of the GIP and GLP-1 receptor pathways for effects on energy homeostasis, body composition, insulin sensitivity, and metabolic function, producing a distinct profile compared to single (GLP-1) receptor agonists studied in the literature.
Tirzepatide (LY3298176) is a dual GIP/GLP-1 receptor agonist investigated in preclinical and clinical research for its effects on metabolic function, body weight regulation, insulin sensitivity, and energy homeostasis. All use is strictly for in-vitro laboratory research only.
Our Tirzepatide 10mg is independently verified at 99.512% HPLC purity. Each batch is tested by an accredited third-party laboratory and comes with a full Certificate of Analysis (COA).
Lyophilised Tirzepatide should be stored at −20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.
Add bacteriostatic water (BAC water) slowly to the vial at a 1–2mL volume. Gently swirl; do not shake. Allow the lyophilised powder to dissolve completely before use in research protocols.
Tirzepatide is a dual agonist targeting the GIP and GLP-1 receptors, while Retatrutide is a triple agonist that also targets the glucagon receptor. In research settings, their differing receptor profiles produce distinct metabolic effects.
Yes. Tirzepatide is legal to purchase in Australia for legitimate in-vitro laboratory and research purposes. It is not approved for human consumption or therapeutic use.
Yes. Every batch of Tirzepatide ships with a downloadable COA including HPLC purity percentage, mass spectrometry identity confirmation, sterility results, and LAL endotoxin assay data.
Yes. Peptide Labs ships Tirzepatide nationwide across Australia via Australia Post with tracking. Orders placed before 11PM AEST are dispatched the next business day.
Tirzepatide 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. It has not been evaluated by the Therapeutic Goods Administration (TGA) or any other regulatory body for human use. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable Australian laws and regulations.
No questions yet — be the first to ask about this product.
Recent peer-reviewed studies from PubMed related to Tirzepatide. Provided for research context — not medical advice.
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff AM, le Roux CW, Stefanski A, et al. · The New England journal of medicine · 2025
PMID: 39536238
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021
PMID: 34186022
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Heise T, DeVries JH, Urva S, et al. · Diabetes care · 2023
PMID: 36857477
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial
Hannon TS, Chao LC, Barrientos-Pérez M, et al. · Lancet (London, England) · 2025
PMID: 40975112
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.